Long-Term Second Malignancies in Prostate Cancer Patients Treated With Low-Dose-Rate Brachytherapy and Radical Prostatectomy
Marie-Pier St-Laurent(University of British Columbia), Scott Tyldesley(BC Cancer Agency), Katherine Sunderland(BC Cancer Agency), Peter C. Black(University of British Columbia), Sarah Hamilton(BC Cancer Agency), Martin Gleave(University of British Columbia), Mira Keyes(BC Cancer Agency), Jeremy Hamm, Michael McKenzie(Provincial Health Services Authority), Stacy Miller, George Acland(Christchurch Hospital)
Cited by 8
Related Papers
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
|European Urology|2017|798
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer
|International Journal of Radiation Oncology*Biology*Physics|2016|736
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
|European Urology|2017|644
Volumetric Modulated Arc Therapy for Delivery of Prostate Radiotherapy: Comparison With Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy
|International Journal of Radiation Oncology*Biology*Physics|2008|532